Home > Insights > Supreme Court of the United States’ decision on Myriad case

Author: Matthew Spencer
13 June, 2013

The Supreme Court of the United States has today handed down its opinion in the Myriad case (ASSOCIATION FOR MOLECULAR PATHOLOGY, ET AL., PETITIONERS v. MYRIAD GENETICS, INC., ET AL.).

Justice Thomas delivered the opinion of the court:

“We hold that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but that cDNA is patent eligible because it is not naturally occurring.”

Author

Matthew Spencer
Partner

Phone this number +44 (0)1223 883000

Email this address mspencer@boult.com

CPC4 Capital Park
Cambridge Road
Cambridge
CB21 5XE